Dan Hertz joined the Department of Clinical Pharmacy in the College of Pharmacy in April 2013. He received his PharmD from the Ernest Mario School of Pharmacy at Rutgers University and his PhD in pharmaceutical sciences from the University of North Carolina Eshelman School of Pharmacy.

Interested in developing tools for individualizing cancer treatment, his current work focuses on the optimal use of taxane chemotherapy in patients with cancer. The approaches being developed include identifying an ideal systemic drug exposure target to maximize efficacy while avoiding unnecessary toxicity, particularly as it relates to chemotherapy-induced peripheral neuropathy. Hertz is also interested in understanding the influence of patient genetics on cancer treatment outcomes, with a particular interest in the clinical translation of DPYD testing to ensure safe fluoropyrimidine chemotherapy dosing. He uses several approaches to discover the effect of germline variants on treatment outcomes and translate these findings into clinical practice. Much of this work is conducted through collaboration with medical oncologists at the University of Michigan Rogel Cancer Center and within NCTN Groups including SWOG and Alliance.